Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 3/20 | 0.39 |
| ▸ | ME2 | P23368 | 1/20 | 0.34 |
| ▸ | ME1 | P48163 | 1/20 | 0.34 |
| ▸ | ME3 | Q16798 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080669 | 0.84 | HDAC6 (0.39) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL12294290 | 0.82 | ATM (0.43) | NPC1RAB9A | |
| SCHEMBL19942194 | 0.81 | VNN1 (0.39) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL2566143 | 0.80 | VNN1 (0.49) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL2560721 | 0.78 | VNN1 (0.47) | HDAC6HDAC3HDAC1HDAC2NPC1 | |
| SCHEMBL2560278 | 0.78 | HDAC3 (0.53) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL12288410 | 0.76 | HDAC6 (0.65) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL2560412 | 0.76 | GPR55 (0.45) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL27899243 | 0.76 | VNN1 (0.38) | HDAC6HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL12288597 | 0.74 | VNN1 (0.44) | HDAC6HDAC3HDAC1HDAC2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| CN-112047926-A | Certain amino-pyrimidines, compositions thereof and methods of use thereof | 赛特凯恩蒂克公司 | 2020-12-08 | — | — | CN | disclosed |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3698795-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2560653-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560488-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133888-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133920-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133888-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | HDAC6 2861/4885HDAC3 3047/4885HDAC1 1672/4885 |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | HDAC6 2667/4885HDAC3 3180/4885HDAC1 2308/4885 |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | HDAC6 2667/4885HDAC3 3180/4885HDAC1 2308/4885 |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | HDAC6 1208/4885HDAC3 602/4885HDAC1 786/4885 |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | HDAC6 2861/4885HDAC3 3047/4885HDAC1 1672/4885 |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | HPRT1, TYMP, TYMS | HDAC6 3656/4885HDAC3 4217/4885HDAC1 3791/4885 |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | HPRT1, TYMP, TYMS | HDAC6 3656/4885HDAC3 4217/4885HDAC1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.